Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
April 18th 2025Panelists discuss how medical professionals anticipate new IL-17 inhibitor data, particularly from head-to-head trials like BE BOLD. Interest is growing in sonelokimab, an IL-17A/F nanobody (Papp, 2021). Further research is needed on long-term efficacy, safety, and optimal patient selection.
Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis
April 18th 2025James Song, MD, FAAD, discusses how topical Janus kinase inhibitors offer distinct advantages for children with moderate atopic dermatitis by providing effective inflammation control without the adverse effects of topical corticosteroids, particularly in sensitive areas like the face and intertriginous regions.
Utility of Head-to-Head Studies in Atopic Dermatitis and Future Research Directions
April 18th 2025Panelists discuss how data from head-to-head clinical trials comparing different therapeutic options in atopic dermatitis inform treatment decisions while exploring critical gaps in research that future studies need to address.
Utility of Head-to-Head Studies in Psoriasis Management
April 18th 2025Panelists discuss how head-to-head trials in psoriasis provide direct efficacy and safety comparisons between IL-17 inhibitors and other drug classes. Studies like BE RADIANT, BE VIVID, and IXORA-R highlight bimekizumab’s and ixekizumab’s superiority over secukinumab and ustekinumab. CLARITY and COBRA compare IL-17 to IL-23 inhibitors, while IMMerge and BE BOLD explore risankizumab’s role. These trials inform treatment decisions by guiding biologic selection based on efficacy, durability, and safety.
Things to Consider With Treatment Sequencing for Pediatric Atopic Dermatitis
April 18th 2025James Song, MD, FAAD, discusses how the treatment of pediatric atopic dermatitis (AD) demands personalized consideration of disease severity, patient age, affected areas, and treatment history. Ruxolitinib cream may address gaps by providing a nonsteroidal alternative with fewer adverse effects, potentially delaying or reducing systemic therapy needs.
Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results
Panelists discuss how poorly managed generalized pustular psoriasis (GPP) flares can lead to recurrent hospitalizations and significant morbidity, while reviewing Effisayil 2 trial results that demonstrated the effectiveness of maintenance therapy in preventing flares and sustaining long-term disease control through targeted inhibition of the IL-36 pathway.
Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results
Panelists discuss how a generalized pustular psoriasis (GPP) emergency case highlights the rapid onset, systemic complications, and treatment challenges of this condition, while reviewing Effisayil 1 trial results that demonstrated spesolimab’s efficacy in quickly resolving pustulation through IL-36 pathway inhibition, representing a significant advancement in targeted therapy for acute flares.
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
April 11th 2025Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumab’s 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumab’s 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.
Determining Appropriate Candidates for JAK Inhibitor Therapy
April 11th 2025Panelists discuss how to identify suitable patients for JAK inhibitor therapy by evaluating disease severity, medical history, risk factors, and individual treatment goals while considering contraindications and safety considerations.
Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis
April 11th 2025Jennifer Soung, MD, discusses how the biggest frustrations parents express about current treatment options for their children with AD, including limited effectiveness, side effects, and the lack of long-term solutions.
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
April 11th 2025Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.
The Impact of Atopic Dermatitis on Quality of Life and the Role of New Therapies
April 11th 2025Jennifer Soung, MD, discusses how pediatric atopic dermatitis (AD) burdens entire families through sleep disruption and emotional toll. Parents seek effective nonsteroidal options beyond current treatments. Convenient topical Janus kinase (JAK) inhibitors could improve adherence and outcomes.
Prior and Current Treatments for Patients With GPP
Panelists discuss how prior and current treatments for patients with generalized pustular psoriasis (GPP) have evolved from traditional systemic therapies with significant limitations to newer targeted biologics and small molecules that specifically address the underlying IL-36 pathway dysregulation, offering improved efficacy and safety profiles for this rare but severe condition.
Recognizing the Flares and Triggers of GPP
Panelists discuss how recognizing the flares and triggers of generalized pustular psoriasis requires vigilant monitoring for warning signs such as fever, malaise, and spreading erythema, while understanding that common precipitating factors include medication withdrawals, infections, pregnancy, and certain drugs that can rapidly transform stable disease into acute, potentially life-threatening episodes requiring immediate intervention.
Safety Considerations for IL-17 Inhibitors
April 4th 2025Panelists discuss how IL-17 inhibitors are generally well-tolerated, but common adverse effects include infections, particularly candidiasis, and potential increased suicidal ideation risk. Patients should be informed of candidiasis risk, especially with bimekizumab (Gordon, 2022), and monitored for mood changes, as IL-17s and IL-23s may impact mental health (Blauvelt, 2023). Open discussions help assess risks while ensuring treatment benefits.
Selecting and Dosing IL-17 Inhibitors in Psoriasis
April 4th 2025Panelists discuss how IL-17 inhibitors are considered for plaque psoriasis based on disease severity, comorbidities, and patient preference. Selection factors include efficacy, safety, access, and cost. Clinical trial data guide choices, but real-world factors impact use. Dosing varies: secukinumab (300 mg weekly for 5 weeks, then monthly), ixekizumab (160 mg at week 0, then 80 mg biweekly for 12 weeks, then monthly), brodalumab (210 mg weekly for 3 weeks, then biweekly), and bimekizumab (320 mg every 4 weeks for 16 weeks, then every 8 weeks). Dosing and device options influence prescribing decisions.